Endovia Health Sciences, Inc.

Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

The FDA's Center for Veterinary Medicine determined that CannEpil, a CBD/THC oral solution for canine bone cancer pain, qualifies as a minor use under the MUMS program, establishing eligibility for the conditional-approval pathway. Endovia and partner Lupvindol BioSciences will meet with the FDA on November 19, 2026, for a Pre-Submission Conference to align on the development program, and are finalizing U.S.-based manufacturing in parallel. Subject to regulatory approval, a potential veterinary launch is targeted for 2027; CannEpil remains investigational and is not yet approved or conditionally approved.

•21d ago

Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways

Endovia Health Sciences closed the initial funding tranche from C/M Capital Master Fund, LP to advance development and commercialization of CannEpil®, its exclusively licensed cannabinoid pharmaceutical asset. The capital funds a U.S. FDA-regulated veterinary program targeting cancer-related pain in dogs under INAD File No. 14145, plus international commercialization efforts. Management also highlighted a favorable federal backdrop: an FDA botanical drug initiative and proposed H.R. 10150, which would grant 12-year market exclusivity for qualifying botanical drugs, though the bill remains pending.

•1mo ago

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Endovia Health Sciences welcomed the federal government's support for rescheduling marijuana to Schedule III, viewing it as a pivotal shift that removes historical impediments to cannabinoid research and FDA pathways. The company expects to submit a request for a pre-submission conference with the FDA in the coming week to discuss the regulatory pathway for its lead asset CannEpil®. Endovia is concurrently expanding its pipeline of cannabinoid formulations and working with capital partners to finalize financing for development and potential acquisitions.

•1mo ago

Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program

Endovia Health Sciences announced that the FDA Center for Veterinary Medicine has established an Investigational New Animal Drug (INAD) file for its CannEpil program, marking the first regulatory milestone under its collaboration with Lupvindol Biosciences. The company is initially developing CannEpil to manage cancer-related pain in dogs, addressing an unmet need where no FDA-approved therapies currently exist. Effective August 24, the company rebranded from Splash Beverage Group and changed its ticker symbol to EDVA, reflecting its strategic shift to a cannabinoid-based health sciences platform.

•2mo ago